1 2 3 4 5 6 7 8	The appropriateness of empirical antibiotic therapy in the management of symptomatic urinary tract infection patients-A cross sectional study in Nairobi County, Kenya Hellen A. Onyango <sup>1,2,3*</sup> , Derek J Sloan <sup>1</sup> , Katherine Keenan <sup>2</sup> , Mike Kesby <sup>2</sup> , Caroline Ngugi <sup>3</sup> ,
9	Humphrey Gitonga <sup>4</sup> , Robert Hammond <sup>1</sup> .
10	
11 12 13	<ul> <li><sup>1</sup>School of Medicine, University of St Andrews, Scotland, United Kingdom.</li> <li><sup>2</sup>School of Geography and Sustainable Development, University of St Andrews, Scotland,</li> </ul>
14	United Kingdom.
15	<sup>3</sup> College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology,
16	Nairobi, Kenya.
17 18 19	<sup>4</sup> Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
20 21 22 23	Corresponding author* Hellen A. Onyango; E-mail: <u>hao1@st-andrews.ac.uk</u> , <u>helenonyango@jkuat.ac.ke</u>
24	
25	
26	
27	
28	
29	
30	
31 22	
32 33	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 34 Abstract

Background: In low- and- middle income countries, symptomatic urinary tract infection (UTI)
patients are often prescribed antibiotics without microbiological confirmation. UTIs caused by
antibiotic resistant bacteria are increasingly common and this heightens the risk of empirical
treatment failure. This study evaluates the appropriateness of empirical antibiotic therapy to
symptomatic UTI patients.

40 **Methods:** A hospital-based, cross-sectional study was conducted in Nairobi County, Kenya 41 among symptomatic adult and child patients. UTI was defined as a monoculture growth with 42 colony counts of  $\geq 10^4$  cfu/ml. Antimicrobial susceptibility testing (AST) was performed by 43 the Kirby-Bauer disc diffusion method. Empirical therapy was considered appropriate if the 44 pathogen isolated was susceptible to the prescribed antibiotic and inappropriate if pathogen 45 was resistant to prescribed antibiotic.

46 **Results:** A total of 552 participants were enrolled with a median age of 29 years (IQR:24-36). The majority were female; 398 (72%). Of the 552, 274 (50%) received empirical antibiotic 47 therapy, 95/274 (35%) were confirmed to have UTI by culture. The antibiotics most frequently 48 prescribed were fluoroquinolones [ciprofloxacin in 80 (30%) and levofloxacin 43 (16%)], 49 amoxicillin-clavulanic-acid in 48 (18%), and nitrofurantoin in 32 (12%). Amongst the 95 50 51 patients with bacteriological confirmation of UTI, 50 (53%) received appropriate empirical antibiotic therapy, whilst for 38 (40%) participants, the therapy was inappropriate. 52 Appropriateness of empirical therapy to 7 (7%) patients could not be determined as the 53 antibiotics prescribed were not in the AST panel. 54

55 Conclusion: The complexity of appropriate empirical treatment for UTIs is compounded by 56 high levels of resistance in UTI pathogens. AMR surveillance strategies that could help in 57 designing appropriate empirical regimens in resource constrained settings should be adopted 58 for optimal empiric therapy.

## 59 **1. Introduction**

Antimicrobial resistance (AMR) is the ability of microorganisms to circumvent the toxic action 60 of antimicrobial substances that otherwise would kill or inhibit them.<sup>1</sup> The prevalence of 61 resistance in common disease-causing bacteria has increased globally, both in healthcare and 62 community settings.<sup>2</sup> Consequently, the WHO has now listed AMR as an emerging public 63 health threat believed to account for over 700,000 deaths per year.<sup>3</sup> The burden of AMR is 64 estimated to be highest in low-and-middle income countries (LMICs), particularly in Africa,<sup>4</sup> 65 where morbidity and mortality from infectious diseases is high, and health facilities less well-66 resourced than those in high income regions.<sup>5,6</sup> Large regional, interdisciplinary studies, 67 including the Holistic Approach to Unravel Antimicrobial resistance in East Africa (HATUA) 68 project which was run across Kenya, Uganda, and Tanzania, have reported multiple drivers of 69 AMR. Relevant factors ranged from inappropriate antibiotic prescriptions, to widespread non-70 71 prescription-based dispensing of antimicrobials for self-medication, antibiotic use in animals, environmental factors such as sanitation, as well as social-economic and structural drivers 72 including the cost of seeking healthcare.<sup>7-9</sup> In hospital settings, factors such as inadequate 73 diagnostic capabilities, poor antibiotic stewardship practices, poor adherence to treatment 74 guidelines and lack of AMR surveillance have been associated with resistance.<sup>6,10</sup> 75

76 Urinary tract Infections (UTIs) are among the most common community-acquired bacterial infections, and are the second most frequent clinical indication for antibiotic use.<sup>11</sup> after 77 respiratory infections.<sup>12</sup> Patients with suspected UTI are often initiated on antibiotic treatment 78 79 before culture results are available. However, in some cases, approximately 40% of the bacteria that cause UTI are resistant to the antimicrobials prescribed.<sup>13</sup> In the recent past, the prevalence 80 of multi-drug resistant (MDR) bacteria associated with UTI has increased,<sup>14</sup> making selection 81 82 of therapy for community acquired UTI complex. Guidelines for uncomplicated UTI treatment recommend customization of therapy based on local practice, circulating resistant organisms, 83

drug availability and price.<sup>15</sup> In Nairobi County, Kenya where this study was undertaken, nitrofurantoin 100mg, amoxicillin-clavulanic-acid 625mg, and amikacin 15-30mg/kg are recommended empirical antimicrobial therapy for community acquired UTIs.<sup>16</sup> For recurrent infections, the guideline recommends that empirical therapy be guided by previous culture results pending urine culture and sensitivity results. Once available, therapy is tailored to prescribe the most narrow spectrum efficacious antibiotic wherever possible.<sup>16</sup>

The selection of empirical therapy for UTI management is dependent on knowledge of 90 circulating pathogens and their antimicrobial resistance patterns.<sup>17</sup> Of concern, therefore, is the 91 92 lack of susceptibility data for community acquired UTI's in many LMICs, including Kenya. This is mostly due to challenges with culture and susceptibility testing, some of which include 93 infrastructural constraints, limited funding, prolonged turnaround times (TAT), and lack of 94 skilled personnel.<sup>4,18</sup> There is relatively limited information on the appropriateness of empirical 95 antibiotic therapy in the management of community acquired UTI's in LMICs. This study seeks 96 to address the paucity of microbiological information on management of microbiologically 97 confirmed UTI in symptomatic patients and evaluates the appropriateness of empirical UTI 98 treatment based on culture and susceptibility results. 99

# **2. Materials and Methods**

### 101 **2.1. Study design**

A hospital-based cross-sectional study design was employed to recruit adult and child patients
with UTI-like symptoms between July 2022 to April 2023.

### 104 2.2 Study setting

105 The participants were recruited from Mama Lucy Kibaki Hospital (MLKH) and Mbagathi106 County Hospital (MCH) located within Nairobi County, as shown in Figure 1. The Kenyan

107 healthcare system is structured in a hierarchical manner consisting of six levels I-VI in 108 ascending order. MLKH and MCH are Level - V public referral hospitals. MCH and MLKH 109 serve a large catchment area comprising both the middle and low socio-economic groups. The 110 two hospitals were selected as there was limited information on the resistance profiles of 111 circulating uropathogens and UTI patients are often treated empirically without culture 112 confirmation.



113



### 115 2.3 Participant recruitment and sample collection

A resident clinician identified adult ( $\geq 18$  years) and child (5-17 years) outpatients presenting with one or more symptoms suggestive of UTI or for other causes that made the clinician to believe they might also have a UTI. The symptoms included lower abdominal pain, dysuria, strong persistent urge to urinate, haematuria, frequent micturition and/or unexplained fever ( $\geq 38^{\circ}$ C), persistent irritability, and suprapubic pain/tenderness to palpation in children. In addition to meeting the criteria of a presumptive UTI case, the participants had to meet the following criteria: report living within a 50 km radius from the hospital facility, have a mobile

telephone number, and be able to speak/understand/write either English or Kiswahili. The study 123 objectives were explained and patients willing to participate were taken through informed 124 consent document (ICD) in their preferred language. Consent was obtained from adult patients 125 (≥18 years). Assent and consent were obtained for participants aged 13-17 years. Parents/ 126 guardians of participants aged < 13 years consented on their behalf. Consenting participants 127 signed and dated the consent forms. Participants/guardians who were not able to sign marked 128 the consent with a thumb print. Consenting participants were issued with a unique identifiable 129 number which linked their bar-coded consent form, demographic data questionnaire, and urine 130 sample collection container. Self-collected midstream urine on a 20 mL sterile plain screw-131 capped universal bottles was obtained from each patient after guidance on the collection 132 procedure. Parents/guardians were guided on how to collect midstream urine from their 133 children. The samples were stored in a cool box (4°C) and transported to the Kenya Medical 134 Research Institute (KEMRI) laboratory for processing within 2 hours. 135

136 2.4 Data collection

A questionnaire was used to collect self-reported demographic information (age, gender), and previous antimicrobial use. Data regarding empirical antibiotic treatment was obtained from prescriptions administered to the patients during the hospital visit. All data were captured electronically into an epicollect database (<u>https://five.epicollect.net is a free open-source data</u> collection tool) and later linked to the laboratory urine culture results.

142 2.5 Microbiological tests

### 143 **2.5.1** Urine culture

Using a standard sterile loop, an aliquot (10µl) of urine was plated directly on Cystine lactose
electrolyte deficient agar (CLED), blood agar (BA), and MacConkey agar (Oxoid, Basingstoke,
UK), and incubated aerobically at 35-37°C for 24 hours. After an overnight incubation,

quantification of colony forming units (cfu's) was done by counting the number of colonies on 147 a plate and multiplying by the dilution factor, as previously described by Miles and Misra.<sup>19</sup> 148 Pure bacterial growth yielding colony counts of  $\geq 10,000$  (10<sup>4</sup>) cfu/ml was interpreted as a 149 confirmed UTI case. A mixed culture (with more than one colony type) or growth of <10,000 150  $(10^4)$  cfu/ml were non-confirmatory for UTI. 151

The organisms were identified to the species level using colonial morphological characteristics 152 on CLED, BA, MacConkey agar (Oxoid, Basingstoke, UK), Gram-stain (Sigma-Aldrich, USA) 153 and standard biochemical tests. Sulfide Indole Motility test, Methyl Red, Oxidase, Urease, 154 Triple Sugar Iron, and citrate utilization was used to identify Gram negative organisms.<sup>20</sup> 155 Coagulase, Catalase, and haemolytic patterns on BA was used to confirm the presence of Gram-156 positive bacteria. Where necessary, the analytical profile index (API 20E) test was used to 157 confirm the identity of strains following the manufacturer's guidelines (BioMerieux, 158 Charbonnieres, LesBains, France). 159

160

### 2.5.2 Antimicrobial susceptibility test

Antimicrobial susceptibility testing (AST) was performed according to the Kirby Bauer disc 161 diffusion method.<sup>21</sup> The panel of antibiotic discs (Oxoid, Basingstoke, UK) tested included first 162 line; amoxicillin-clavulanic-acid (20/10 µg), nitrofurantoin (300 µg), sulfamethoxazole 163 trimethoprim (23.75/1.25 µg), and second- line; ciprofloxacin (5 µg) antibiotics used in the 164 treatment of UTI as per local practice.<sup>16</sup> Other antibiotics included in the panel were 165 ceftazidime (30 µg), ceftriaxone (30 µg), cefepime (30 µg), cefoxitin (30 µg), gentamycin (10 166 μg), cefuroxime (30 μg), erythromycin (15 μg), and linezolid (30 μg). Susceptibility or 167 resistance to the tested antibiotics were determined using the zone diameter interpretative 168 criteria (breakpoints) according to the CLSI guidelines.<sup>22</sup> Isolates that showed intermediate 169 resistance to a given antibiotic were interpreted as resistant to that antibiotic. E. coli (ATCC-170

171 25922) and *S. aureus* (ATCC-25923) were used as quality control organisms to validate
172 antibiotic discs potency and quality of the test media.

### **2.6 Evaluation of the appropriateness of empirical treatment**

Appropriateness of empiric treatment was assessed by evaluating the treatment prescribed 174 during the initial hospital visit with the subsequent laboratory urine culture and susceptibility 175 results. The hospital visit during which the patient was recruited, and urine sample obtained, 176 was defined as the initial visit. Empirical treatment was taken as any antibiotic treatment 177 prescribed to the patient during the initial visit prior to urine culture results. Appropriateness 178 was assessed on an individual patient basis for those patients whose urine specimen yielded 179 significant bacterial growth for UTI ( $\geq 10^4$  cfu/ml). Appropriate empirical antibiotic therapy 180 (AEAT) was considered if a UTI was confirmed on urine culture and the antibiotics prescribed 181 were effective in inhibiting growth of the isolated pathogen *in vitro*.<sup>23</sup> Inappropriate empirical 182 antibiotic therapy (IEAT) was defined as UTI confirmed on laboratory culture, but with an 183 isolated pathogen which was resistant to the antibiotic prescribed in vitro.23 AEAT was 184 expressed as the percentage of patients with a culture positive urine specimen, and isolated 185 pathogen tested as sensitive to the antibiotic prescribed. Conversely, IAET was expressed as 186 187 the percentage of patients with a culture positive urine specimen who had an empiric prescription for which the isolated pathogen was tested as resistant. 188

189 2.7 Statistical analysis

Data were downloaded from epicollect into Microsoft Excel (Microsoft Corp, Redmond,
Washington, USA) and were analysed using STATA 16 (StataCorp. 2019. Stata 183 Statistical
Software: Release 16. College Station, TX: StataCorp LLC). The questionnaire data were
linked to urinalysis, empirical prescription and AST data using anonymous patient identifiers.
Baseline characteristics of the study population were reported as median (interquartile range)

195 [IQR]) for age, or as counts and percentages for categorical data. Differences between 196 categorical variables were compared using the  $\chi^2$  test or Fishers exact test where applicable. 197 Statistical significance was considered at probability value of < 0.05.

## 198 2.8 Ethical approval

This study received approval from University of St. Andrews Teaching and Research Ethics Committee, United Kingdom [Approval no. MD15749]; Jomo Kenyatta University of Agriculture and Technology Institutional Ethics Review Board, Kenya [Approval no. JKU/IERC/02316/0166], National Commission for Science Technology and Innovation, Kenya [Approval no. P/21/12520]. Nairobi Metropolitan services, MLKH and MDH provided approvals for access to the study sites. Informed consent was obtained from each participant included in the study.

## 206 **3. Results**

## 207 3.1. Characteristics of study participants

Participants characteristics are shown in Table 1. Five hundred and fifty-two were enrolled.
The majority were adult outpatients 494 (89.4%), and females accounted for 398 (72%). The
most frequent age bracket was 21-30 with a median age of 29 years (IQR:24-36). Among the
552 enrolled patients, 236 (43%) had taken medication 2 weeks prior to enrolment, 168 (71%)
of these had taken antibiotics, while 68 (29%) had taken medications other than antibiotics.

217

Variable	Response	UTI (+) *	UTI (-) *
		n (%)	n= (%)
Average		124 (22.5)	428 (77.5)
Gender	Male	32 (26)	122 (29)
	Female	92 (74)	306 (71)
Age	5-10	9 (7.2)	21 (5)
	11-20	12 (9.6)	37 (8.6)
	21-30	56 (45)	183 (43)
	31-40	25 (20)	103 (24)
	41-50	12 (9.6)	54 (13)
	>50	10 (8)	30 (7)
Medication taken in two	No medication	76 (61)	240 (56)
weeks prior to recruitment	Yes-antibiotics	37 (30)	131 (31)
-	Yes-other medications	11 (8.8)	57 (13)

#### 218 Table 1: Basic demographic characteristics of participants

219

Demographic and clinical characteristics of study participants. KEY: UTI (+) \*-Culture
 confirmed UTI positive, UTI (-) \*-Culture confirmed UTI negative.

### **3.2 Proportion of microbiologically confirmed UTI**

The overall proportion of culture confirmed UTI among the studied population was 22.5%, 223 (124/552), being significantly higher in females than males, Table 1. Of these, 274 (49.6%) 224 225 received empirically prescribed antibiotic treatment, 242 (43.8%) did not receive any antibiotic treatment, while for 36 (6.5%), it was not known whether they received an antibiotic or not 226 (participants could not be reached by phone or failed to come back to the hospital for the 227 laboratory results). Amongst the 274 that received empirical antibiotic therapy, urine culture 228 confirmed UTI in 95 (35%). Of the 242 that didn't receive therapy, 27 (11.1%) had UTI 229 confirmed. Among those whose therapy status was not known, 2 (5.5%) had confirmed UTI. 230 There was a significant difference in UTI detection between those who received empirical 231 therapy and those who did not, p-value of < 0.05. 232

### 233 3.3 Microbiological characteristics

A total of 124 bacterial isolates were characterised from the 552 urine samples analysed, 97 (78%) of which were Gram-negative. The predominant uropathogen was *Escherichia coli* 64 (52%); followed by *Klebsiella* spp. 21 (17%); *Staphylococcus aureus*, 14 (11.3%); coagulase negative Staphylococcus (CoNS), 7 (5.6%); *Enterococcus faecalis*, 6 (4.8%), *Proteus* spp. 7 (5.6%); and *Acinetobacter baumanni*, 1 (0.8%). *Pseudomonas aeruginosa* 2 (1.6), and

239 *Citrobacter koseri* 2 (1.6%).

### 240 3.4 Antimicrobial resistance patterns

Antimicrobial resistance profiles of the 124 isolated UTI pathogens are shown in Table 2. For 241 Gram negative organisms, resistance towards common UTI treatments -β-lactams, 242 fluoroquinolones, and aminoglycosides (BFQA) ranged from 24% to 57%. Within the bacterial 243 predominant *E*. coli, the uropathogen, showed high resistance 244 groups, to sulfamethoxazole/trimethoprim at 77%, ciprofloxacin at 61%, amoxicillin-clavulanic acid at 245 47%, and ceftriaxone at 52%, while nitrofurantoin was the most effective agent for E. coli. The 246 overall resistance of Gram-positive bacteria was 52% for sulfamethoxazole trimethoprim, 67% 247 248 for ciprofloxacin, and 26% for amoxicillin-clavulanic-acid. Nitrofurantoin and linezolid were the most effective agents against Gram-positive isolates. 249

- 250
- 251

Organism groups	No. of Organisms tested	Antimicrobial resistance n (%) <sup>2</sup>												
	n <sup>1</sup>	AMP	AMC	CAZ	CRO	FEP	FOX	GEN	CIP	SXT	NIT	СХМ	ERY	LNZ
E. coli	64	53(83)	30(47)	29(45)	33(52)	29(45)	8(12)	15(22)	39(61)	49(77)	3(5)	58(91)	N/A	N/A
Klebsiella	21	20(95)	13(62)	13(62)	14(67)	14(67)	6(29)	7(33)	19(91)	14(67)	10(48)	19(91)	N/A	N/A
spp. <i>Proteus</i> spp.	7	4(57)	4(57)	0	0	0	0	1(14)	2(29)	4(57)	7(100)	3(43)	N/A	N/A
P. aeruginosa	2	2(100)	2(100)	1(50)	1(50)	0	2(100)	0	0	2(100)	2(100)	2(100)	N/A	N/A
C. koseri	2	1(50)	0	0	1(50)	0	0	0	0	0	1(50)	1(50)	N/A	N/A
A. baumanni	1	1(100)	1(100)	1(100)	1(100)	1(100)	1(100)	1(100)	1(100)	1(100)	1(100)	1(100)	N/A	N/A
S. aureus	14	12(86)	4(29)	N/A	N/A	N/A	3(21)	3(21)	8(57)	11(79)	1(7)	N/A	8(57)	0
CoNS	7	7(100)	3(43)	N/A	N/A	N/A	3(43)	1(14)	5(71)	1(14)	1(14)	N/A	55(71)	0
E. faecalis	6	0	0	N/A	N/A	N/A	6(100)	6(100)	5(83)	2(33)	1(17)	N/A	6(100)	0

#### 252 Table 2: Antimicrobial resistance profiles of isolated UTI pathogens

253

254 KEY: AMP-Ampicillin; AMC-Amoxicillin-clavulanic acid; CAZ-Ceftazidime; CRO-Ceftriaxone; FEP-Cefepime; FOX- Cefoxitin; GEN-Gentamycin; CIP-Ciprofloxacin;

255 SXT-Sulfamethoxazole/Trimethoprim; NIT-Nitrofurantoin; CXM-Cefuroxime; ERY-Erythromycin; LNZ-Linezolid; CoNS-Coagulase negative staphylococci; n<sup>1</sup>-Number of

isolates within a particular species; n  $(\%)^2$  -frequency of resistant isolates in relation to n<sup>1</sup> expressed in percentage for individual antibiotics; N/A -not applicable, antibiotics not tested in the isolates.

## 258 3.5 Empirical antimicrobial prescribing

There were 15 antibiotics and antibiotic combinations prescribed empirically. Most of the 259 patients 244 (89.0%) received one antibiotic, 28 (10.2%) received 2 antibiotics, while 2 (0.7%) 260 received 3 antibiotics, Figure 2. Antimicrobial treatment was prescribed to 49.6% of all 261 patients, with a first line empirical treatment recommended in national guidelines utilised in 262 29.6% of cases. The most frequently prescribed antibiotics were ciprofloxacin (30.3%), 263 264 amoxicillin clavulanic acid (17.5%), levofloxacin (15.7%), nitrofurantoin (11.6%), and cefuroxime (10.6%), while the least prescribed were sulfamethoxazole trimethoprim (1.1%), 265 266 and cefepime at (0.4%). Ceftriaxone/ciprofloxacin and cefixime/azithromycin were the most prescribed combination therapies at 4.7% and 3.2% respectively. 267

268



269

270 Figure 2: An overview of empirical antimicrobial prescribing at the outpatient departments of

271 MLKH and MCH, Nairobi County, Kenya.

272

## **3.6.** Appropriateness of empirical antibiotic treatment (AEAT)

Of the 95 patients with bacteriological confirmation of UTI, the antimicrobial susceptibility 274 results were compared with the empirical therapy prescribed. The most prescribed antibiotics 275 empirically were found to be inappropriate as follows: Ciprofloxacin was prescribed 27 times 276 but in 11 cases (41%), the isolated organisms were resistant; for amoxicillin clavulanic acid, in 277 12 (40%) out of the 30 prescriptions, organisms were resistant; for nitrofurantoin, 4 (27%) of 278 the 15 prescriptions proved to be inappropriate, and finally, cefuroxime was prescribed 7 times, 279 280 but 6 (88%) cases were inappropriate. Overall, most patients 50 (53%) received appropriate empirical therapy, while for 38 (40%), the therapy was found to be inappropriate. The 281 appropriateness of empirical therapy to 7 (7%) patients could not be determined as the 282 antibiotics prescribed (levofloxacin, cefixime/azithromycin) were not in the AST panel, Figure 283 3. 284



285

Figure 3: Evaluation of appropriateness of empirical therapy. Appropriateness or inappropriateness
 was expressed as a percentage based on n=95 patients who had laboratory confirmed UTI and had
 susceptible or resistant AST results respectively.

## 289 **4. Discussion**

This study determined the proportion of microbiologically confirmed UTI cases among 552 290 symptomatic patients and evaluated the appropriateness of empiric antibiotic therapy 291 prescribed to symptomatic UTI patients. Our findings suggest that in about 40% of cases, 292 empirical antimicrobial prescribing for UTI proves inappropriate in the context of subsequent 293 urine culture and susceptibility results. IEAT can be associated with significant adverse 294 outcomes. While changing to the right antibiotic upon receipt of the culture results is beneficial 295 and necessary for targeted therapy, it may not fully mitigate the disadvantages of not having 296 the correct antibiotic from the onset.<sup>23</sup> IEAT may promote selection pressures that can result in 297 the growth of resistant bacterial populations, which not only affects the individual patient, but 298 also poses a broader public health threat to everyone. Furthermore, IEAT can result in 299 unnecessary healthcare costs including expenses associated with additional tests and treatment 300 for complications.<sup>24</sup> These consequences underscore the importance of judicious antibiotic 301 prescribing to optimize patient outcomes and preserve the effectiveness of antibiotics for future 302 generations. 303

It is challenging to find comparable studies because of the wide variation in the way that IEAT 304 is defined. Nevertheless, a recent study by Maina et al investigated the appropriateness of 305 306 antibiotic use across a range of disease conditions among 1502 patients in Kenyan public hospitals. Among other findings, these results showed that 26% of 94 patients who had UTI 307 and 68% of 135 patients in the surgical unit received empirical treatment that was inappropriate 308 for the pathogens isolated.<sup>25</sup> Higher rates ranging from 54% to 87% of IEAT in UTI have been 309 reported by other studies.<sup>26–30</sup> However, while our study defined inappropriate treatment 310 according to the criteria outlined by Davey et al,23 these studies had a combination of 311 312 definitions which included: antibiotic prescriptions without bacteriological confirmation,

prescription of an antibiotic to which isolated pathogen was resistant, inappropriate antibiotic
dosage, lack of sensitivity testing, and therapy not being within the treatment guidelines.

Overall, only 1 in 5 patients suspected of having UTI had bacteriological confirmation by the 315 criteria applied in this study (monoculture growth of 10<sup>4</sup> cfu/ml). However, a considerable 316 proportion of the patients 168 (30%), had taken antibiotics prior to the initial hospital visit. 317 This highlights the challenge of conducting and interpreting microbiology culture results in 318 patients previously exposed to antibiotics, as prior research has demonstrated that antibiotic 319 exposure is a strong predictor of negative culture outcomes.<sup>31</sup> This further illustrates the 320 321 difficulty healthcare providers face in deciding on the need for antibiotic prescriptions based solely on clinical symptoms. Evidence on how well symptoms predict the true presence of UTI 322 when compared with urine culture has shown varied results, and is estimated to have an error 323 rate of up to 33%.<sup>31</sup> In this study, 11% of patients had laboratory confirmation of UTIs, yet they 324 did not receive empirical treatment. These findings are comparable to those reported by Zhue 325 et al and Rama et al, in which 15.7% and 12.5% patients respectively, did not receive empirical 326 treatment but were confirmed to have UTI by the culture method.<sup>26,29</sup> While treating only after 327 the microbiological results are obtained ensures that the correct antimicrobial therapy is chosen, 328 the strategy increases the risk of a worse outcome. These findings highlights the need of a near 329 point-of-care test that can detect UTI and provide preliminary antimicrobial susceptibility 330 reports to guide decision-making in UTI management. 331

There was a wide variation of empirical antimicrobial prescribing practise among prescribers, with differences in preference for certain antimicrobials seen. This was most striking in relation to the prescription of fluoroquinolones (ciprofloxacin, levofloxacin),  $\beta$ -lactam/ $\beta$ -lactamase inhibitor combinations (AMC), and nitrofurantoin. Despite being a second line therapy, more than half 140 (51%) of the patients received fluoroquinolones. This is high considering the already reported high resistance<sup>32</sup> and adverse ecological effects<sup>33</sup> associated with this class of

antimicrobials. A further 6.3% of the patients received sulfamethoxazole trimethoprim despite 338 this antibiotic not being among the recommended empirical treatments,<sup>16</sup> and local resistance 339 patterns already exceeding 20%.<sup>32</sup> One possible explanation to these findings is the absence 340 of sufficient laboratory support, which influences prescription pattern and choice, leading to a 341 predominance of broad-spectrum prescriptions and polypharmacy.<sup>34</sup> The high-grade resistance 342 exhibited against amoxicillin-clavulanic-acid makes this agent suboptimal for UTI treatment 343 in the absence of laboratory support, notwithstanding that it is recommended in the national 344 guidelines as first-line empirical therapy. This illustrates a clear need for more comprehensive 345 346 national surveillance and perhaps a review of the guidelines. In contrast, nitrofurantoin was an appropriate agent for both Gram-positive and Gram-negative bacteria, and its empirical use is 347 encouraged in the absence of any contraindication.<sup>35</sup> 348

349 The high proportion of resistance amongst UTI pathogens reported in this study and in neighbouring countries,<sup>17,36</sup> can likely be explained by records of inappropriate antibiotic use 350 which is one of the key drivers of AMR. This could be caused by inadequate microbiology 351 diagnostics, lack of updated antibiotic susceptibility data, and self-treatment using over-the-352 counter antibiotics, a wide-spread practise in many LMICs.<sup>37</sup> Some challenges identified in 353 laboratory diagnostics have been the long turnaround time (TAT), high cost of investigation 354 and the lack of trust in and utilization of laboratory results by clinicians.<sup>38</sup> Performing culture 355 and susceptibility tests may contribute to higher healthcare costs for patients. However, its 356 357 essential to consider this added expense in light of the potential savings from avoiding inappropriate or unnecessary treatment that are not supported by laboratory data. 358

This study has some limitations. First, the patients were only recruited from the outpatient departments of two health facilities, so generalisation of findings to other settings, even within Kenya, should be made with caution. Nevertheless, patients were sequentially recruited without stringent selection criteria and the same approach was taken to investigation of every

participant which minimised bias and increased the likelihood that the results reflected the 363 general population and routine medical practices. Further, the findings do not give insights into 364 the appropriateness of prescription in private health facilities or in inpatients. However, it is 365 considered satisfactory to provide background information on appropriateness of empirical 366 treatment. Secondly, the population of outpatients who presented with symptoms suggestive of 367 UTI may have had other underlying conditions given that UTI symptoms may over-lap with 368 369 those of other diseases. However, we assumed that all antibiotics prescribed during initial hospital visit before the AST results (when each patient was recruited into the study and urine 370 371 collected) were for the UTI episode.

## **5.** Conclusion

The study has demonstrated that achieving appropriate empirical antibiotic treatment for UTIs is a difficult task, especially in the era of increased AMR in clinical infections, situations of limited resource, and much habitual over-the counter antibiotic use. At present, optimal empiric therapy is not being achieved. This situation could be improved if capacity for delivering accurate and timely susceptibility results to clinicians to aid their clinical decision making could be achieved. Finally, it is crucial to enhance routine AMR surveillance to support effective antimicrobial stewardship practices in healthcare facilities.

#### **380** Authors contribution

HAO.: conceptualization, laboratory investigations, data curation, formal analysis, and original
drafting of the manuscript. RJHH.: Conceptualization, supervision, reviewing and editing. DS.:
Conceptualization, supervision, reviewing and editing MK.: Conceptualization, supervision,
reviewing and editing KK.: Conceptualization, supervision, reviewing and editing. CWN.:
Supervision of laboratory data collection in Kenya. HG.: Laboratory investigations and data
curation.

### 387 Acknowledgements

- 388 The authors would like to thank all patients for their participation, and the laboratory and
- clinical teams at MLKH, MDH and KEMRI-CMR for their support during the study period.
- 390 Funding
- 391 This work was supported by the Scottish Funding Council (SFC) through the Global
- 392 Challenges Research Fund (GCRF).
- Transparency declarations
- 394 None to declare

- -

#### 411 References

- Harbottle H, Thakur S, Zhao S *et al.* Genetics of antimicrobial resistance. *Anim Biotechnol.* 2006;17:111–24.
- World Health Organization. Global Antimicrobial Resistance and Use Surveillance
  System 2022. https://www.who.int/publications/i/item/9789240062702
- 416 3. Neill JO'. Antimicrobial Resistance: Tackling a crisis for the health and wealth of
  417 nations. The Review on Antimicrobial Resistance, 2014.
- 418 4. Murray CJ, Ikuta KS, Sharara F *et al*. Global burden of bacterial antimicrobial resistance
  419 in 2019: a systematic analysis. *Lancet*. 2022;**399**:629–55.
- 420 5. Petti CA, Polage CR, Quinn TC *et al.* Laboratory Medicine in Africa: A Barrier to
  421 Effective Health Care. *Clin Infect Dis* 2006;42:377–82.
- 422 6. Elbireer AM, Jackson JB, Sendagire H *et al.* The Good, the Bad, and the Unknown:
  423 Quality of Clinical Laboratories in Kampala, Uganda. *PLoS One.* 2013;8:1–6.
- Asiimwe BB, Kiiru J, Mshana SE *et al.* Protocol for an interdisciplinary cross-sectional
  study investigating the social, biological and community-level drivers of antimicrobial
  resistance (AMR): Holistic Approach to Unravel Antibacterial Resistance in East Africa
  (HATUA). *BMJ Open*2021;11:414-18. http://bmjopen.bmj.com/
- 8. Ndaki PM, Mushi MF, Mwanga JR *et al.* Dispensing antibiotics without prescription at
  community pharmacies and accredited drug dispensing outlets in tanzania: A crosssectional study. *Antibiotics*. 2021;10:1–15.
- Green DL, Keenan K, Fredricks KJ *et al.* The role of multidimensional poverty in
  antibiotic misuse: a mixed-methods study of self-medication and non-adherence in
  Kenya, Tanzania, and Uganda. *Lancet Glob Heal.* 2023;11:59–68.
- 10. Doron S, Davidson LE. Antimicrobial stewardship. *Mayo Clin Proc.* 2011;86:1113–23.
- 435 11. Morgan MG, McKenzie H. Controversies in the laboratory diagnosis of community436 acquired urinary tract infection. *Eur J Clin Microbiol Infect Dis.* 1993;12:491–504.
- Llor C, Bjerrum L. Antimicrobial resistance: Risk associated with antibiotic overuse and
  initiatives to reduce the problem. *Ther Adv Drug Saf.* 2014;**5**:229–41.
- 439 13. McCowan C, Bakhshi A, McConnachie A et al. E. coli bacteraemia and antimicrobial

resistance following antimicrobial prescribing for urinary tract infection in the
community. *BMC Infect Dis.* 2022;22:1–10.

- 442 14. Mazzariol A, Bazaj A, Cornaglia G. Multi-drug-resistant Gram-negative bacteria
  443 causing urinary tract infections: a review. *J Chemother* 2017;29:2–9.
  444 https://doi.org/10.1080/1120009X.2017.1380395
- 15. Gupta K, Hooton TM, Naber KG et al. International clinical practice guidelines for the 445 treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update 446 by the Infectious Diseases Society of America and the European Society for 447 Diseases. Microbiology and Infectious Clin Infect Dis 2011;52:103-20. 448 https://academic.oup.com/cid/article/52/5/e103/388285 449
- 450 16. KNH. Kenyatta National Hospital-Guidelines for empiric antimicrobial therapy 2023.
  451 https://healthsciences.uonbi.ac.ke/sites/default/files/2023-06/KNH Empiric
  452 Antimicrobial Therapy Guidelines.pdf
- Maldonado-barragán AA, Mshana SE, Keenan K *et al.* Predominance of multidrugresistant (MDR) bacteria causing urinary tract infections (UTIs) among symptomatic
  patients in East Africa: a call for action. *JAC-Antimicrobial Resist* 2023;6:1–36.
  https://doi.org/10.1101/2023.06.13.23291274
- Iskandar K, Molinier L, Hallit S *et al.* Surveillance of antimicrobial resistance in lowand middle-income countries: a scattered picture. *Antimicrob Resist Infect Control.* 2021
  ;10: 63-82.
- 460 19. Miles AA, Misra SS, Irwin JO. The estimation of the bactericidal power of the blood. J
  461 *Hyg (Lond)*. 1938;**38**:732–49.
- 462 20. Chesbrough M. District Laboratory Practice in Tropical countries, Part 2, Second
  463 Edition. Cambridge University Press, UK; 2006.
- Bauer, A. W., Kirby, W. M. M., *et al* Antibiotic susceptibility testing by a standardized
  single disk method. *Am J Clin Pathol.* 1966;45:493.
- 466 22. CLSI. Performance Standards for Antimicrobial Disk Suspectibility Tests, Approved
  467 Standard-Thirteenth Edition. M02. 2018.
- 468 23. Davey PG, Marwick C. Appropriate vs. inappropriate antimicrobial therapy. Clin
  469 Microbiol Infect 2008;14:15–21. http://dx.doi.org/10.1111/j.1469-0691.2008.01959.x

Esparcia A, Artero A, Eiros JM *et al.* Influence of inadequate antimicrobial therapy on
prognosis in elderly patients with severe urinary tract infections. *Eur J Intern Med*2014;25:523–7. http://dx.doi.org/10.1016/j.ejim.2014.04.009

- 473 25. Maina M, Mwaniki P, Odira E *et al.* Antibiotic use in Kenyan public hospitals:
  474 Prevalence, appropriateness and link to guideline availability. *Int J Infect Dis*475 2020;99:10–18. https://doi.org/10.1016/j.ijid.2020.07.084
- 476 26. Alkhawaldeh R, Farha RA, Hammour KA *et al.* The Appropriateness of Empiric
  477 Treatment of Urinary Tract Infections in a Tertiary Teaching Hospital in Joran: A Cross478 Sectional Study. *Antibiotics*. 2022;11: 629.
- 479 27. Vellinga A, Cormican M, Hanahoe B *et al.* Antimicrobial management and
  480 appropriateness of treatment of urinary tract infection in general practice in Ireland.
  481 *BMC Fam Pract.* 2011;12:108
- 482 28. Tünger Ö, Dinç G, Özbakkaloglu B *et al.* Evaluation of rational antibiotic use. *Int J*483 *Antimicrob Agents.* 2000;15:131–5.
- Zhu H, Chen Y, Hang Y *et al.* Impact of inappropriate empirical antibiotic treatment on
  clinical outcomes of urinary tract infections caused by Escherichia coli: a retrospective
  cohort study. J Glob Antimicrob Resist 2021;26:148–53.
  https://doi.org/10.1016/j.jgar.2021.05.016
- Marquet K, Liesenborgs A, Bergs J *et al.* Incidence and outcome of inappropriate inhospital empiric antibiotics for severe infection: A systematic review and meta-analysis. *Crit Care* 2015;19:63.
- 491 31. Schmiemann G, Kniehl E, Gebhardt K *et al.* The Diagnosis of Urinary Tract Infection.
  492 *Dtsch Ärzteblatt Int* 2010;**107**:361–7.

493 32. Kiiru S, Maina J, Katana J *et al.* Bacterial etiology of urinary tract infections in patients
494 treated at Kenyan health facilities and their resistance towards commonly used
495 antibiotics. *PLoS* One 2023;18:277-279.
496 http://dx.doi.org/10.1371/journal.pone.0277279

497 33. Stahlmann R, Lode HM. Risks associated with the therapeutic use of fluoroquinolones.
498 *Expert Opin Drug Saf* 2013;12:497–505.
499 https://www.tandfonline.com/doi/abs/10.1517/14740338.2013.796362

- 500 34. Chokshi A, Sifri Z, Cennimo D, *et al.* Global contributors to antibiotic resistance. *J Glob*501 *Infect Dis* 2019;11:36–42.
- So2 35. Pouwels KB, Freeman R, Muller-Pebody B *et al.* Association between use of different
   antibiotics and trimethoprim resistance: Going beyond the obvious crude association. J
   Antimicrob Chemother 2018;73:1700–7.
- 505 36. Silago V, Moremi N, Mtebe M *et al.* Multidrug-Resistant Uropathogens Causing
  506 Community Acquired Urinary Tract Infections among Patients Attending Health
  507 Facilities in Mwanza and Dar es Salaam, Tanzania. *Antibiotics.* 2022;11:1–13.
- 508 37. Do NTT, Vu HTL, Nguyen CTK *et al.* Community-based antibiotic access and use in
  509 six low-income and middle-income countries: a mixed-method approach. *Lancet Glob*510 *Heal.* 2021;9:610–9.
- 38. Alemnji GA, Zeh C, Yao K *et al.* Strengthening national health laboratories in subSaharan Africa: A decade of remarkable progress. Trop Med Int Heal. 2014;19:450–8.

- E 7 1